DK2838918T3 - Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler - Google Patents

Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler Download PDF

Info

Publication number: DK2838918T3
Authority: DK; Denmark
Prior art keywords: methods; molecules; heterodimer; preparing; preparing heterodimer
Prior art date: 2012-04-20

Application number

DK13720615.7T

Other languages

English (en)

Inventor

Kruif Cornelis Adriaan De

Linda Johanna Aleida Hendriks

Ton Logtenberg

Original Assignee

Merus Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-20

Filing date

2013-04-19

Publication date

2019-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2838918(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-19 Application filed by Merus Nv filed Critical Merus Nv

2019-08-12 Application granted granted Critical

2019-08-12 Publication of DK2838918T3 publication Critical patent/DK2838918T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK13720615.7T 2012-04-20 2013-04-19 Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler DK2838918T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261635935P	2012-04-20	2012-04-20
PCT/NL2013/050294 WO2013157954A1 (en)	2012-04-20	2013-04-19	Methods and means for the production of ig-like molecules

Publications (1)

Publication Number	Publication Date
DK2838918T3 true DK2838918T3 (da)	2019-08-12

Family

ID=48289584

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13720615.7T DK2838918T3 (da)	2012-04-20	2013-04-19	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
DK13720614.0T DK2838917T3 (da)	2012-04-20	2013-04-19	Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13720614.0T DK2838917T3 (da)	2012-04-20	2013-04-19	Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler

Country Status (25)

Country	Link
US (12)	US9248182B2 (da)
EP (4)	EP2838917B1 (da)
JP (8)	JP6272299B2 (da)
KR (9)	KR102104601B1 (da)
CN (5)	CN104520320B (da)
AU (4)	AU2013249986B2 (da)
CA (2)	CA2871068C (da)
CY (2)	CY1122153T1 (da)
DK (2)	DK2838918T3 (da)
EA (3)	EA201491908A1 (da)
ES (2)	ES2743399T3 (da)
HK (2)	HK1206039A1 (da)
HR (2)	HRP20191409T1 (da)
HU (2)	HUE045945T2 (da)
LT (2)	LT2838917T (da)
MX (4)	MX360109B (da)
NZ (4)	NZ630551A (da)
PL (2)	PL2838917T3 (da)
PT (2)	PT2838917T (da)
RS (2)	RS59263B1 (da)
SG (6)	SG11201406770WA (da)
SI (2)	SI2838917T1 (da)
SM (2)	SMT201900488T1 (da)
WO (2)	WO2013157954A1 (da)
ZA (2)	ZA201407835B (da)

Families Citing this family (427)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
JP4836451B2 (ja)	2002-07-18	2011-12-14	メルスベーヴェー	抗体混合物の組換え生産
EP2395016A3 (en)	2003-05-30	2012-12-19	Merus B.V.	Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
DK3050963T3 (da)	2005-03-31	2019-12-09	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
CA2647846C (en)	2006-03-31	2016-06-21	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
CN105177091A (zh)	2006-03-31	2015-12-23	中外制药株式会社	用于纯化双特异性抗体的抗体修饰方法
ES2378407T3 (es)	2006-09-01	2012-04-12	Therapeutic Human Polyclonals, Inc.	Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
KR101485197B1 (ko)	2006-09-07	2015-01-23	크루셀 홀란드 비.브이.	인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2194066B1 (en)	2007-09-26	2016-03-09	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
EP2409991B1 (en)	2009-03-19	2017-05-03	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
TWI682995B (zh)	2009-03-19	2020-01-21	日商中外製藥股份有限公司	抗體恆定區域改變體
JP5616428B2 (ja)	2009-04-07	2014-10-29	ロシュグリクアートアクチェンゲゼルシャフト	三価の二重特異性抗体
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102712696A (zh)	2009-09-16	2012-10-03	弗·哈夫曼-拉罗切有限公司	包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US10150808B2 (en)	2009-09-24	2018-12-11	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant regions
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CN102791866B (zh)	2010-02-08	2015-07-29	瑞泽恩制药公司	共有轻链小鼠
US10435458B2 (en)	2010-03-04	2019-10-08	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variants with reduced Fcgammar binding
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
EP2598530A2 (en)	2010-07-29	2013-06-05	Xencor, Inc.	Antibodies with modified isoelectric points
PH12013500974A1 (en)	2010-11-17	2013-07-08	Chugai Pharmaceutical Co Ltd	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN103403025B (zh)	2011-02-28	2016-10-12	弗·哈夫曼-拉罗切有限公司	单价抗原结合蛋白
BR112013019975A2 (pt)	2011-02-28	2017-08-01	Hoffmann La Roche	proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
MX343729B (es)	2011-04-08	2016-11-18	Amgen Inc	Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
EP2739740B1 (en)	2011-08-05	2019-10-02	Regeneron Pharmaceuticals, Inc.	Humanized universal light chain mice
KR101870555B1 (ko)	2011-08-23	2018-06-22	로슈 글리카트 아게	T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2787078B1 (en)	2011-10-31	2019-05-22	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
BR112014018575A2 (pt) *	2012-01-26	2017-07-04	Amgen Inc	polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
CN104736174B (zh)	2012-07-06	2019-06-14	根马布私人有限公司	具有三重突变的二聚体蛋白质
BR112015006824A2 (pt)	2012-09-27	2017-07-04	Merus B V	anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
BR112015007120A2 (pt)	2012-10-08	2017-12-12	Roche Glycart Ag	anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
WO2014084607A1 (ko)	2012-11-27	2014-06-05	아주대학교산학협력단	항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
CA2898100C (en)	2013-01-14	2023-10-10	Xencor, Inc.	Novel heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
AU2014207549B2 (en)	2013-01-15	2018-12-06	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
EA031214B1 (ru)	2013-02-26	2018-12-28	Роше Гликарт Аг	Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
CA2896370A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
AU2014232416B2 (en)	2013-03-15	2017-09-28	Xencor, Inc.	Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
KR102266819B1 (ko)	2013-04-29	2021-06-18	에프. 호프만-라 로슈 아게	Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
TW201920285A (zh)	2013-04-29	2019-06-01	瑞士商赫孚孟拉羅股份公司	遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
EA201501063A1 (ru)	2013-04-29	2016-05-31	Ф. Хоффманн-Ля Рош Аг	СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PL3027642T3 (pl) *	2013-07-31	2021-01-11	Amgen Inc.	Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)
ES2881306T3 (es)	2013-09-27	2021-11-29	Chugai Pharmaceutical Co Ltd	Método para la producción de heteromultímeros de polipéptidos
JP6422956B2 (ja)	2013-10-11	2018-11-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性ドメイン交換共通可変軽鎖抗体
LT3083680T (lt)	2013-12-20	2020-04-10	F. Hoffmann-La Roche Ag	Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
PL3089996T3 (pl)	2014-01-03	2021-12-13	F. Hoffmann-La Roche Ag	Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
CN111057147B (zh)	2014-01-06	2023-11-10	豪夫迈·罗氏有限公司	单价血脑屏障穿梭模块
RU2727639C2 (ru)	2014-01-15	2020-07-22	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
ES2833599T3 (es)	2014-02-28	2021-06-15	Merus Nv	Anticuerpo que se une a ERBB-2 y ERBB-3
CA2941030A1 (en)	2014-02-28	2015-09-03	Merus N.V.	Antibodies that bind egfr and erbb3
ES2872475T3 (es)	2014-03-21	2021-11-02	Regeneron Pharma	Animales no humanos que producen proteínas de unión de dominio único
EP3699195A3 (en)	2014-03-28	2020-11-04	Xencor, Inc.	Bispecific antibodies that bind to cd38 and cd3
UA117289C2 (uk)	2014-04-02	2018-07-10	Ф. Хоффманн-Ля Рош Аг	Мультиспецифічне антитіло
SG10202107077QA (en)	2014-04-02	2021-07-29	Hoffmann La Roche	Method for detecting multispecific antibody light chain mispairing
BR112016029935A2 (pt)	2014-06-26	2017-10-31	Hoffmann La Roche	?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP2982692A1 (en)	2014-08-04	2016-02-10	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
FI3177643T5 (fi)	2014-08-04	2023-11-28	Hoffmann La Roche	T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
US11952421B2 (en)	2014-10-09	2024-04-09	Bristol-Myers Squibb Company	Bispecific antibodies against CD3EPSILON and ROR1
JP6576456B2 (ja)	2014-11-06	2019-09-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
KR20170078677A (ko)	2014-11-06	2017-07-07	에프. 호프만-라 로슈 아게	Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
RU2753902C2 (ru)	2014-11-20	2021-08-24	Ф.Хоффманн-Ля Рош Аг	Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
EP3023437A1 (en)	2014-11-20	2016-05-25	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
EP3221356B1 (en)	2014-11-20	2020-09-02	F.Hoffmann-La Roche Ag	T cell activating bispecific antigen binding molecules against folr1 and cd3
DK3221357T3 (da)	2014-11-20	2020-08-10	Hoffmann La Roche	Fælles letkæder og fremgangsmåder til anvendelse
PH12017500968B1 (en)	2014-11-26	2022-06-03	Xencor Inc	Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en)	2014-11-26	2020-01-07	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CD38
WO2016087416A1 (en)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Multispecific antibodies
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
CN105820251B (zh) *	2015-01-08	2019-10-15	江苏康宁杰瑞生物制药有限公司	具有共同轻链的双特异性抗体或抗体混合物
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
US11111314B2 (en)	2015-03-19	2021-09-07	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
KR20170129233A (ko)	2015-03-26	2017-11-24	악셀레론 파마 인코포레이티드	폴리스타틴-관련된 융합 단백질 및 이들의 용도
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
AR105089A1 (es)	2015-06-24	2017-09-06	Hoffmann La Roche	ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
RS57928B1 (sr)	2015-07-10	2019-01-31	Merus Nv	Antitela koja vezuju humani cd3
JP6892431B2 (ja)	2015-07-10	2021-06-23	ゲンマブエー／エス	癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
BR112018000696A2 (pt)	2015-07-15	2018-09-18	Genmab As	?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
JP6622396B2 (ja) *	2015-08-26	2019-12-18	バイソンセラピュイティクスインコーポレイテッド	多重特異性抗体プラットフォームおよびその関連方法
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180161A (es)	2015-10-02	2018-05-25	Hoffmann La Roche	Anticuerpos biespecíficos para pd1 y tim3
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
CN108139394B (zh)	2015-10-02	2020-10-30	豪夫迈·罗氏有限公司	用于确定同时结合的基于细胞的fret测定法
US20180282410A1 (en)	2015-10-02	2018-10-04	Hoffmann-La Roche Inc.	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
US20170096485A1 (en)	2015-10-02	2017-04-06	Hoffmann-La Roche Inc.	Bispecific t cell activating antigen binding molecules
WO2017055389A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
EP3356409A2 (en)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispecific t cell activating antigen binding molecules
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
EP3150637A1 (en)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Multispecific antibodies
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055314A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
KR101851380B1 (ko) *	2015-10-12	2018-04-23	아주대학교산학협력단	효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
JP7296728B2 (ja)	2015-10-23	2023-06-23	メルスナムローゼフェンノートシャップ	癌の成長を抑制する結合分子
BR112018006562A2 (pt)	2015-10-29	2018-12-11	Hoffmann La Roche	anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo
WO2017072208A1 (en) *	2015-10-29	2017-05-04	F. Hoffmann-La Roche Ag	Transgenic rabbit with common light chain
JP7254515B2 (ja)	2015-12-01	2023-04-10	ジェンマブビー．ブイ．	抗ｄｒ５抗体およびその使用方法
AU2016365742A1 (en)	2015-12-07	2018-06-21	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and PSMA
AU2016368469B2 (en)	2015-12-09	2023-11-02	F. Hoffmann-La Roche Ag	Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (en)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN106883297B (zh) *	2015-12-16	2019-12-13	苏州康宁杰瑞生物科技有限公司	基于ch3结构域的异二聚体分子、其制备方法及用途
MX2018007781A (es)	2015-12-28	2018-09-05	Chugai Pharmaceutical Co Ltd	Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
MX2018008347A (es)	2016-01-08	2018-12-06	Hoffmann La Roche	Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
RU2746754C2 (ru)	2016-03-14	2021-04-20	Чугаи Сейяку Кабусики Кайся	Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
CN109153728A (zh)	2016-03-21	2019-01-04	埃尔斯塔治疗公司	多特异性和多功能分子及其用途
PE20231511A1 (es)	2016-03-22	2023-09-26	Hoffmann La Roche	Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
WO2017186853A1 (en) *	2016-04-27	2017-11-02	Bcrt Holding Bv	T cell-based bi-specific immunotherapeutics
CA3019524A1 (en)	2016-05-02	2017-11-09	F. Hoffmann-La Roche Ag	The contorsbody - a single chain target binder
JP7301540B2 (ja) *	2016-05-26	2023-07-03	チールーピュージェットサウンドバイオセラピューティクスコーポレイション	抗体の混合物
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh)	2016-06-02	2019-01-16	瑞士商赫孚孟拉羅股份公司	治療方法
CA3026151A1 (en)	2016-06-14	2017-12-21	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
RU2019102008A (ru)	2016-06-28	2020-07-28	Ксенкор, Инк.	Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
EP3478717B1 (en)	2016-07-04	2022-01-05	F. Hoffmann-La Roche AG	Novel antibody format
EA201990293A1 (ru)	2016-07-14	2019-07-31	Генмаб А/С	Мультиспецифичные антитела против cd40 и cd137
CN110267977A (zh)	2016-08-10	2019-09-20	亚洲大学校产学协力团	细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL311603A (en)	2016-09-23	2024-05-01	Merus Nv	Binding molecules that regulate biological activity expressed by a cell
SG10201913263SA (en) *	2016-09-29	2020-03-30	Beijing Hanmi Pharmaceutical Co Ltd	Heterodimeric immunoglobulin constructs and preparation methods thereof
PL3519437T3 (pl)	2016-09-30	2022-01-17	F. Hoffmann-La Roche Ag	Przeciwciała dwuswoiste przeciwko p95HER2
EP3519820B1 (en)	2016-09-30	2020-12-09	H. Hoffnabb-La Roche Ag	Spr-based dual-binding assay for the functional analysis of multispecific molecules
PE20191034A1 (es)	2016-10-14	2019-08-05	Xencor Inc	Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
US20180118811A1 (en) *	2016-10-19	2018-05-03	Invenra Inc.	Antibody constructs
JP7277363B2 (ja)	2016-11-01	2023-05-18	ジェンマブビー．ブイ．	ポリペプチド変異体およびその使用
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
CA3043652A1 (en)	2016-11-18	2018-05-24	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
US11111305B2 (en)	2017-01-09	2021-09-07	Torch Therapeutics	Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
WO2018148445A1 (en)	2017-02-08	2018-08-16	Adimab, Llc	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MA47449A (fr)	2017-02-10	2019-12-18	Genmab Bv	Variants polypeptidiques et ses utilisations
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
KR20240060739A (ko)	2017-02-20	2024-05-08	드래곤플라이 쎄라퓨틱스, 인크.	Her2, nkg2d 및 cd16에 결합하는 단백질
EP3586872A4 (en) *	2017-02-24	2020-12-30	Chugai Seiyaku Kabushiki Kaisha	PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
JP7293121B2 (ja)	2017-03-09	2023-06-19	ジェンマブエー／エス	Ｐｄ－ｌ１に対する抗体
RU2750721C2 (ru)	2017-03-10	2021-07-01	Ф. Хоффманн-Ля Рош Аг	Способ получения мультиспецифических антител
MX2019011520A (es)	2017-03-31	2020-08-03	Genmab Holding B V	Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
IL269656B2 (en)	2017-03-31	2024-06-01	Merus Nv	Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
MX2019011658A (es)	2017-03-31	2019-11-18	Merus Nv	Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
EP3600411A1 (en)	2017-03-31	2020-02-05	Merus N.V.	Antibodies for the treatment of erbb-2/erbb-3 positive tumors
JP7579703B2 (ja) *	2017-04-01	2024-11-08	北京韓美薬品有限公司	抗ｐｄ－ｌ１／抗ｐｄ－１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
AU2018247765B2 (en)	2017-04-03	2023-11-23	F. Hoffmann-La Roche Ag	Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
CN110494452B (zh)	2017-04-03	2023-08-25	豪夫迈·罗氏有限公司	结合steap-1的抗体
EP3606947B1 (en)	2017-04-03	2022-12-21	F. Hoffmann-La Roche AG	Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
PT3606955T (pt)	2017-04-05	2025-01-09	Hoffmann La Roche	Anticorpos biespecíficos que se ligam especificamente a pd1 e a lag3
JOP20190222A1 (ar)	2017-04-11	2019-09-24	Zymeworks Inc	الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
AU2018250875A1 (en)	2017-04-13	2019-10-03	F. Hoffmann-La Roche Ag	An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
EP3625264B9 (en)	2017-05-17	2023-10-25	Merus N.V.	Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
JP2020522254A (ja)	2017-05-31	2020-07-30	エルスターセラピューティクス，インコーポレイテッド	骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
KR20200027944A (ko)	2017-06-07	2020-03-13	젠맵 비. 브이	돌연변이된 igg 육량체에 기초한 치료 항체
EP3638700B8 (en) *	2017-06-14	2024-09-04	Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation	Proteinaceous heterodimer and use thereof
GB201709970D0 (en)	2017-06-22	2017-08-09	Kymab Ltd	Bispecific antigen-binding molecules
JP2020529832A (ja)	2017-06-30	2020-10-15	ゼンコアインコーポレイテッド	ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
AU2018297061B2 (en)	2017-07-06	2021-05-06	Merus N.V.	Antibodies that modulate a biological activity expressed by a cell
KR102715567B1 (ko)	2017-07-06	2024-10-14	메뤼스 엔.페.	세포에 의해 발현된 생물학적 활성을 조정하는 결합 분자
TW201920657A (zh)	2017-07-06	2019-06-01	荷蘭商米樂斯股份有限公司	藉由細胞表現之調控生物活性的抗體
AR112603A1 (es)	2017-07-10	2019-11-20	Lilly Co Eli	Anticuerpos biespecíficos inhibidores de punto de control
WO2019014912A1 (zh) *	2017-07-21	2019-01-24	赵磊	一种异二聚体蛋白及其制备方法
MA49753A (fr)	2017-08-04	2020-06-10	BioNTech SE	Agents de liaison se liant à pd-l1 et cd137 et leur utilisation
JP2020530028A (ja)	2017-08-09	2020-10-15	メルスナムローゼフェンノートシャップ	ＥＧＦＲ及びｃＭＥＴに結合する抗体
US20200317783A1 (en)	2017-10-06	2020-10-08	Ono Pharmaceutical Co., Ltd.	Bispecific antibody
CN111246885B (zh)	2017-10-20	2024-06-11	豪夫迈·罗氏有限公司	从单特异性抗体生成多特异性抗体的方法
TWI832824B (zh)	2017-10-30	2024-02-21	瑞士商赫孚孟拉羅股份公司	自單特異性抗體於活體內產生多特異性抗體之方法
CN111182944B (zh)	2017-11-01	2022-11-22	豪夫迈·罗氏有限公司	双特异性2+1 Contorsbody
CN111295392A (zh)	2017-11-01	2020-06-16	豪夫迈·罗氏有限公司	Compbody–多价靶结合物
EP3704146B1 (en)	2017-11-01	2021-12-15	F. Hoffmann-La Roche AG	Trifab-contorsbody
CN111246884A (zh)	2017-11-01	2020-06-05	豪夫迈·罗氏有限公司	新颖的含有tnf家族配体三聚体的抗原结合分子
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019094637A1 (en)	2017-11-08	2019-05-16	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US20200384084A1 (en)	2017-12-01	2020-12-10	Merus N.V.	Use of bispecific antibody and il-15 for combination therapy
EP3722322A4 (en) *	2017-12-04	2021-09-15	Beijing Hanmi Pharmaceutical Co., Ltd.	ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION
MA51291A (fr)	2017-12-19	2020-10-28	Xencor Inc	Protéines de fusion il-2 fc modifiées
US11192957B2 (en)	2017-12-21	2021-12-07	Hoffmann-La Roche Inc.	Antibodies binding to HLA-A2/WT1
EP3728327A1 (en)	2017-12-22	2020-10-28	F. Hoffmann-La Roche AG	Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3743440A1 (en)	2018-01-24	2020-12-02	Genmab B.V.	Polypeptide variants and uses thereof
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
WO2019148410A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1 antibodies
IL276383B2 (en)	2018-02-06	2024-01-01	Hoffmann La Roche	Treatment of ophthalmological diseases
WO2019153200A1 (zh)	2018-02-08	2019-08-15	北京韩美药品有限公司	抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2021512630A (ja)	2018-02-08	2021-05-20	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
CA3089287A1 (en)	2018-02-08	2019-08-15	Genentech, Inc.	Bispecific antigen-binding molecules and methods of use
TW202438530A (zh)	2018-02-09	2024-10-01	日商小野藥品工業股份有限公司	雙特異性抗體
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
JP2021512624A (ja) *	2018-02-11	2021-05-20	ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇＨａｎｍｉＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
CA3091424A1 (en)	2018-02-20	2019-08-29	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
WO2019190327A2 (en) *	2018-03-30	2019-10-03	Merus N.V.	Multivalent antibody
WO2019195623A2 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
SG11202009884YA (en)	2018-04-09	2020-11-27	Amgen Inc	Growth differentiation factor 15 fusion proteins
EP3781204A4 (en) *	2018-04-17	2022-03-30	Invenra, Inc.	BINDING MOLECULES
CA3097593A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US20210238296A1 (en)	2018-05-03	2021-08-05	Genmab B.V.	Antibody variant combinations and uses thereof
BR112020023187A2 (pt)	2018-05-16	2021-04-20	Janssen Biotech, Inc.	métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t
JP7646361B2 (ja)	2018-06-01	2025-03-17	コンピュジェンリミテッド	抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
MA52951A (fr)	2018-06-22	2021-04-28	Genmab Holding B V	Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
CN112955465A (zh)	2018-07-03	2021-06-11	马伦戈治疗公司	抗tcr抗体分子及其用途
CR20210081A (es)	2018-07-13	2021-06-24	Genmab As	Variantes de anticuerpos anti-cd38 y sus usos.
US20240254252A1 (en)	2018-07-13	2024-08-01	Genmab A/S	Trogocytosis-mediated therapy using cd38 antibodies
GB2576914A (en)	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
CA3113605A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Novel bispecific antibodies for use in the treatment of hematological malignancies
CA3115096A1 (en)	2018-10-03	2020-04-09	Xencor, Inc.	Il-12 heterodimeric fc-fusion proteins
MA53812A (fr)	2018-10-04	2021-08-11	Genmab Holding B V	Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
JP7630426B2 (ja)	2018-10-23	2025-02-17	ドラゴンフライセラピューティクス，インコーポレイテッド	ヘテロ二量体ｆｃ融合タンパク質
SG11202103064YA (en)	2018-10-29	2021-05-28	Hoffmann La Roche	Antibody formulation
US20210369842A1 (en)	2018-11-06	2021-12-02	Genmab A/S	Antibody formulation
JP2022513708A (ja)	2018-12-05	2022-02-09	モルフォシス・アーゲー	多重特異性抗原結合分子
GB201820687D0 (en)	2018-12-19	2019-01-30	Kymab Ltd	Antagonists
JP2022521036A (ja)	2018-12-20	2022-04-05	メルスナムローゼフェンノートシャップ	ＣＬＥＣ１２ＡｘＣＤ３二重特異性抗体及び疾患の治療方法
BR112021012065A2 (pt)	2018-12-21	2021-12-07	Kymab Ltd	Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia
PH12021551484A1 (en)	2018-12-21	2022-04-11	Hoffmann La Roche	Antibodies binding to cd3
JP2022515473A (ja)	2018-12-28	2022-02-18	エフ．ホフマン－ラロシュアーゲー	免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質
WO2020141974A1 (en)	2018-12-31	2020-07-09	Merus N.V.	Truncated multivalent multimers
CA3124768A1 (en)	2018-12-31	2020-07-09	Merus N.V.	Mixed binding domains
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
NL2022494B1 (en)	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
JP2022519082A (ja)	2019-02-01	2022-03-18	ラヴァ・セラピューティクス・ベー・フェー	新規ｃｄ４０結合抗体
SG11202108840XA (en) *	2019-02-14	2021-09-29	Merus Nv	Producing compositions comprising two or more antibodies.
CN114409798A (zh) *	2019-02-14	2022-04-29	美勒斯公司	制备包含两种或更多种抗体的组合物
US20220127376A1 (en)	2019-02-14	2022-04-28	Merus N.V.	Combinations of binding moieties that bind egfr, her2 and her3
WO2020172571A1 (en)	2019-02-21	2020-08-27	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
EP3927431A1 (en)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
SG11202108955QA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Antibody molecules that bind to nkp30 and uses thereof
SG11202109033XA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
GB2599229B (en)	2019-02-21	2024-04-24	Marengo Therapeutics Inc	Multifunctional molecules that bind to calreticulin and uses thereof
JP7612596B2 (ja)	2019-03-01	2025-01-14	ゼンコアインコーポレイテッド	Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
US20220185887A1 (en) *	2019-03-28	2022-06-16	Ab Studio Inc.	Heteromultimeric proteins and methods of use thereof
JP7412440B2 (ja)	2019-03-29	2024-01-12	エフ．ホフマン－ラロシュアーゲー	アビド結合多重特異性抗体を作製する方法
EP3948281A1 (en)	2019-03-29	2022-02-09	F. Hoffmann-La Roche AG	Spr-based binding assay for the functional analysis of multivalent molecules
TW202039578A (zh)	2019-03-29	2020-11-01	荷蘭商美勒斯公司	Cd3結合分子
TW202106715A (zh)	2019-04-25	2021-02-16	瑞士商赫孚孟拉羅股份公司	藉由多肽鏈交換活化之治療性多特異性多肽
KR20220004062A (ko)	2019-04-25	2022-01-11	에프. 호프만-라 로슈 아게	반감기가 연장된 활성화 가능한 치료용 다중특이적 폴리펩티드
CN113728002B (zh) *	2019-04-25	2024-11-12	豪夫迈·罗氏有限公司	通过多肽链交换产生抗体衍生的多肽
MA55881A (fr)	2019-05-09	2022-03-16	Genmab Bv	Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer
MX2021013646A (es) *	2019-05-09	2022-01-31	Merus Nv	Dominios variantes para las proteínas multimerizantes y su separación.
CN119470884A (zh)	2019-05-13	2025-02-18	豪夫迈·罗氏有限公司	抑制干扰的药代动力学免疫测定
JP7317353B2 (ja) *	2019-06-18	2023-07-31	株式会社プロテイン・エクスプレス	ブレビバチルス菌によるヘテロ二量体タンパク質の生産
EP3986928A1 (en)	2019-06-19	2022-04-27	F. Hoffmann-La Roche AG	Method for the generation of a protein expressing cell by targeted integration using cre mrna
WO2020260327A1 (en)	2019-06-26	2020-12-30	F. Hoffmann-La Roche Ag	Mammalian cell lines with sirt-1 gene knockout
WO2021001289A1 (en)	2019-07-02	2021-01-07	F. Hoffmann-La Roche Ag	Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
TW202434297A (zh)	2019-07-05	2024-09-01	日商小野藥品工業股份有限公司	以ｐｄ－１／ｃｄ３雙特異性蛋白質所進行之血液性癌症治療
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
JP2022541332A (ja)	2019-07-26	2022-09-22	ヤンセンバイオテツク，インコーポレーテツド	カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
BR112022001473A2 (pt)	2019-07-30	2022-03-22	Ono Pharmaceutical Co	Anticorpo biespecífico
MX2022001156A (es)	2019-07-31	2022-02-22	Hoffmann La Roche	Anticuerpos que se fijan a gprc5d.
EP4004045A1 (en)	2019-07-31	2022-06-01	F. Hoffmann-La Roche AG	Antibodies binding to gprc5d
US20220332825A1 (en)	2019-08-08	2022-10-20	Ono Pharmaceutical Co., Ltd.	Bispecific protein
KR20220062494A (ko)	2019-08-15	2022-05-17	얀센 바이오테크 인코포레이티드	개선된 단일 사슬 가변 단편을 위한 재료 및 방법
PH12022550306A1 (en)	2019-08-19	2023-07-31	Merus Nv	Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
EP3792283A1 (en)	2019-09-16	2021-03-17	Lava Therapeutics B.V.	Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
KR20220103954A (ko)	2019-10-24	2022-07-25	메뤼스 엔.페.	Her2 및 her3 양성암인 대상의 치료 수단 및 치료 방법
JP2023500686A (ja)	2019-11-01	2023-01-10	インノコアテクノロジーズビー．ブイ．	抗体又は巨大タンパク質の延長された放出の為の剤形物
EP4055046A1 (en)	2019-11-06	2022-09-14	Genmab B.V.	Antibody variant combinations and uses thereof
AU2020395122A1 (en)	2019-12-02	2022-06-09	Regeneron Pharmaceuticals, Inc.	Peptide-MHC II protein constructs and uses thereof
US11739142B2 (en)	2019-12-18	2023-08-29	Hoffmann-La Roche Inc.	Bispecific anti-CCL2 antibodies
WO2021122875A1 (en)	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a2/mage-a4
EP4085251B1 (en)	2020-01-02	2024-07-31	F. Hoffmann-La Roche AG	Method for determining the amount of a therapeutic antibody in the brain
EP4084821A4 (en)	2020-01-03	2024-04-24	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
IL294453A (en)	2020-01-16	2022-09-01	Genmab As	Formulations of cd38 antibodies and uses thereof
CN116407626A (zh)	2020-01-29	2023-07-11	美勒斯公司	用于调节免疫细胞衔接效应的手段和方法
AU2021213735A1 (en)	2020-01-30	2022-09-22	Umoja Biopharma, Inc.	Bispecific transduction enhancer
WO2021155916A1 (en)	2020-02-04	2021-08-12	BioNTech SE	Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
KR20230051615A (ko)	2020-03-13	2023-04-18	얀센 바이오테크 인코포레이티드	Siglec-3/cd33을 결합시키기 위한 물질 및 방법
BR112022015572A2 (pt)	2020-03-18	2022-09-27	Genmab As	Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
WO2021190980A1 (en)	2020-03-22	2021-09-30	Quadrucept Bio Limited	Multimers for viral strain evolution
WO2021203103A2 (en) *	2020-04-03	2021-10-07	Somasekar Seshagiri	Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
BR112022020629A2 (pt)	2020-04-15	2022-11-29	Hoffmann La Roche	Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
JP2023523006A (ja)	2020-04-24	2023-06-01	メルスナムローゼフェンノートシャップ	Ｌｇｒ５及びｅｇｆｒに結合する抗体によるがんの治療
GB2612450A (en)	2020-04-24	2023-05-03	Marengo Therapeutics Inc	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
IL297716A (en)	2020-04-30	2022-12-01	Bristol Myers Squibb Co	Preparations for the treatment of side effects related to cytokines
JP7512394B2 (ja)	2020-05-06	2024-07-08	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
WO2021231278A1 (en)	2020-05-11	2021-11-18	F. Hoffmann-La Roche Ag	Combination therapy with modified pbmcs and an immunoconjugate
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
TW202208425A (zh)	2020-05-21	2022-03-01	荷蘭商美勒斯公司	製造類ｉｇ分子之方法及手段
KR20230017841A (ko)	2020-05-27	2023-02-06	얀센 바이오테크 인코포레이티드	Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
JP2023530961A (ja)	2020-06-19	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｄ３に結合する抗体
JP2023529981A (ja)	2020-06-19	2023-07-12	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	免疫活性化Ｆｃドメイン結合分子
CN115916825A (zh)	2020-06-19	2023-04-04	豪夫迈·罗氏有限公司	与cd3和cd19结合的抗体
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
KR20230025673A (ko)	2020-06-19	2023-02-22	에프. 호프만-라 로슈 아게	CD3 및 FolR1에 결합하는 항체
MX2023000448A (es)	2020-07-08	2023-04-20	Lava Therapeutics N V	Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.
WO2022018294A1 (en)	2020-07-23	2022-01-27	Genmab B.V.	A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
WO2022024024A2 (en)	2020-07-29	2022-02-03	Janssen Biotech, Inc.	Proteins comprising hla-g antigen binding domains and their uses
CA3170741A1 (en)	2020-07-31	2022-02-03	Curevac Ag	Nucleic acid encoded antibody mixtures
JP2023536340A (ja)	2020-08-06	2023-08-24	ビオンテック・ソシエタス・エウロパエア	コロナウイルスｓタンパク質のための結合剤
US11919958B2 (en)	2020-08-19	2024-03-05	Xencor, Inc.	Anti-CD28 compositions
AU2021331076A1 (en)	2020-08-26	2023-04-06	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
AU2021333779A1 (en)	2020-08-26	2023-04-13	Marengo Therapeutics, Inc.	Methods of detecting TRBC1 or TRBC2
WO2022046920A2 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP4210747A1 (en)	2020-09-10	2023-07-19	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
AU2021342342A1 (en)	2020-09-10	2023-04-13	Genmab A/S	Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
CN116391037A (zh)	2020-09-24	2023-07-04	豪夫迈·罗氏有限公司	具有基因敲除的哺乳动物细胞系
IL301513A (en)	2020-10-02	2023-05-01	Genmab As	Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
WO2022081516A1 (en)	2020-10-13	2022-04-21	Janssen Biotech, Inc.	Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
US20240025992A1 (en)	2020-10-22	2024-01-25	Janssen Biotech, Inc.	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
JP2023548375A (ja)	2020-11-04	2023-11-16	メルスナムローゼフェンノートシャップ	Ｅｒｂｂ３変異陽性がんを有する対象を治療するための手段及び方法
US20240010748A1 (en)	2020-11-10	2024-01-11	Shanghai Qilu Pharmaceutical Research And Development Centre Ltd.	Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
WO2022122973A1 (en)	2020-12-10	2022-06-16	LAVA Therapeutics N.V.	Antibodies that bind gamma-delta t cell receptors
TW202237656A (zh)	2020-12-15	2022-10-01	荷蘭商美勒斯公司	利用結合ｌｇｒ５與ｅｇｆｒ之抗體治療癌症
EP4263609A1 (en)	2020-12-17	2023-10-25	F. Hoffmann-La Roche AG	Anti-hla-g antibodies and use thereof
JP2024506416A (ja)	2020-12-18	2024-02-13	メルス・ナムローゼ・フェンノートシャップ	抗体組成物
CN116601175A (zh)	2020-12-18	2023-08-15	豪夫迈·罗氏有限公司	用于靶向疗法的前体蛋白和试剂盒
CN116670282A (zh)	2020-12-22	2023-08-29	豪夫迈·罗氏有限公司	靶向xbp1的寡核苷酸
WO2022148732A1 (en)	2021-01-06	2022-07-14	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en)	2021-01-11	2022-07-14	F. Hoffmann-La Roche Ag	Immunoconjugates
CN116888473A (zh)	2021-02-18	2023-10-13	豪夫迈·罗氏有限公司	用于解析复杂、多步骤抗体相互作用的方法
BR112023017099A2 (pt)	2021-02-26	2023-11-21	Lava Therapeutics N V	Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
WO2022184659A1 (en)	2021-03-01	2022-09-09	Quadrucept Bio Limited	Antibody domains & multimers
WO2022192403A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en)	2021-03-10	2024-01-02	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and GPC3
CN117377694A (zh)	2021-03-24	2024-01-09	詹森生物科技公司	包含cd3抗原结合结构域的蛋白质及其用途
AU2022244453A1 (en)	2021-03-24	2023-11-09	Janssen Biotech, Inc.	Antibody targeting cd22 and cd79b
JP2024514077A (ja)	2021-03-31	2024-03-28	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
AU2022251985A1 (en)	2021-03-31	2023-10-19	Merus N.V.	Novel multispecific antibodies
GB2623199A (en)	2021-04-08	2024-04-10	Marengo Therapeutics Inc	Multifunctional molecules binding to TCR and uses thereof
CN117321078A (zh)	2021-04-30	2023-12-29	豪夫迈·罗氏有限公司	针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
EP4329800A1 (en)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
IL308300A (en)	2021-05-07	2024-01-01	Genmab As	PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
CN117062837A (zh)	2021-05-12	2023-11-14	江苏恒瑞医药股份有限公司	特异性结合rankl和ngf的抗原结合分子及其医药用途
CN117120478A (zh)	2021-05-14	2023-11-24	江苏恒瑞医药股份有限公司	一种抗原结合分子
CA3221735A1 (en)	2021-06-18	2022-12-22	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
IL309319A (en)	2021-06-21	2024-02-01	Genmab As	Combined dosage regimen CD137 and PD-L1 binding agents
BR112023026966A2 (pt)	2021-07-02	2024-03-12	Hoffmann La Roche	Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
CN117480180A (zh)	2021-07-14	2024-01-30	江苏恒瑞医药股份有限公司	特异性结合hgfr和egfr的抗原结合分子及其医药用途
KR20240036570A (ko)	2021-07-22	2024-03-20	에프. 호프만-라 로슈 아게	이종이량체 Fc 도메인 항체
JP2024527977A (ja)	2021-07-27	2024-07-26	ノヴァブ，インコーポレイテッド	免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023006809A1 (en)	2021-07-27	2023-02-02	Morphosys Ag	Combinations of antigen binding molecules
IL309120A (en)	2021-07-28	2024-02-01	Hoffmann La Roche	Methods and compositions for the treatment of cancer
KR102351147B1 (ko) *	2021-08-02	2022-01-14	주식회사 바이오뱅크힐링	블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR20240051280A (ko)	2021-09-06	2024-04-19	젠맵 에이/에스	Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
JP2024533457A (ja)	2021-09-13	2024-09-12	ヤンセンバイオテツク，インコーポレーテツド	がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体
US20230116446A1 (en) *	2021-09-21	2023-04-13	Qilu Puget Sound Biotherapeutics Corporation	HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
US20240270874A1 (en)	2021-09-23	2024-08-15	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-klb antibodies and uses
US20250019455A1 (en)	2021-09-24	2025-01-16	Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
KR20240067099A (ko)	2021-09-30	2024-05-16	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항-il23 항체 융합 단백질 및 용도
IL311548A (en)	2021-10-06	2024-05-01	Merus Nv	Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
US11814437B2 (en)	2021-10-08	2023-11-14	Genmab A/S	Antibodies binding to CD30 and CD3
CN118139648A (zh)	2021-10-14	2024-06-04	豪夫迈·罗氏有限公司	用于治疗癌症的替代的PD1-IL7v免疫缀合物
CA3234731A1 (en)	2021-10-14	2023-04-20	F. Hoffmann-La Roche Ag	New interleukin-7 immunoconjugates
WO2023067138A1 (en)	2021-10-21	2023-04-27	LAVA Therapeutics N.V.	Uses of gamma delta t cell activating antibodies
KR20240099376A (ko)	2021-11-03	2024-06-28	얀센 바이오테크 인코포레이티드	암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
EP4433505A1 (en)	2021-11-19	2024-09-25	Merus N.V.	Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
AU2022392829A1 (en)	2021-11-22	2024-07-11	Janssen Biotech, Inc.	Compositions comprising enhanced multispecific binding agents for an immune response
EP4437344A1 (en)	2021-11-25	2024-10-02	F. Hoffmann-La Roche AG	Quantification of low amounts of antibody sideproducts
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
KR20240139065A (ko)	2022-02-07	2024-09-20	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Psma 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이들의 의약적 용도
TW202342535A (zh)	2022-02-11	2023-11-01	大陸商江蘇恆瑞醫藥股份有限公司	免疫綴合物及其用途
TW202346353A (zh)	2022-03-07	2023-12-01	荷蘭商美勒斯公司	利用結合EGFR及cMET之抗體的治療
EP4490189A1 (en)	2022-03-07	2025-01-15	Merus N.V.	Combination therapy including antibodies that bind egfr and cmet
MX2024011128A (es)	2022-03-14	2024-09-18	Jiangsu Hengrui Pharmaceuticals Co Ltd	Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
WO2023174521A1 (en)	2022-03-15	2023-09-21	Genmab A/S	Binding agents binding to epcam and cd137
MX2024011468A (es)	2022-03-23	2024-09-25	Hoffmann La Roche	Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
CN119421890A (zh)	2022-04-19	2025-02-11	豪夫迈·罗氏有限公司	改进的生产细胞
EP4522657A1 (en)	2022-05-12	2025-03-19	Genmab A/S	Binding agents capable of binding to cd27 in combination therapy
EP4522275A1 (en)	2022-05-12	2025-03-19	Genmab A/S	Binding agents capable of binding to cd27 in combination therapy
EP4285926A1 (en)	2022-05-30	2023-12-06	LAVA Therapeutics N.V.	Combination treatment for chronic lymphocytic leukemia
WO2023232961A1 (en)	2022-06-03	2023-12-07	F. Hoffmann-La Roche Ag	Improved production cells
EP4292609A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Variant antibodies that bind gamma-delta t cell receptors
TW202405004A (zh)	2022-06-23	2024-02-01	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合dll3和cd3的抗原結合分子及其醫藥用途
NL2032398B1 (en)	2022-07-06	2024-01-23	Academisch Ziekenhuis Leiden	Bispecific antibody and uses thereof
WO2024027815A1 (zh)	2022-08-05	2024-02-08	江苏恒瑞医药股份有限公司	特异性结合gucy2c和cd3的抗原结合分子及其医药用途
TW202413436A (zh)	2022-08-05	2024-04-01	荷蘭商美勒斯公司	治療去勢抗性前列腺癌的手段和方法
TW202423970A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh)	2022-10-10	2024-08-01	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024079069A1 (en)	2022-10-12	2024-04-18	F. Hoffmann-La Roche Ag	Method for classifying cells
TW202432177A (zh)	2022-10-31	2024-08-16	丹麥商珍美寶股份有限公司	Ｃｄ３８抗體及其用途
WO2024095173A1 (en)	2022-11-02	2024-05-10	Janssen Biotech, Inc.	Methods of treating cancers
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
WO2024104988A1 (en)	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Recombinant binding proteins with activatable effector domain
WO2024104933A1 (en)	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Antigen binding molecules
TW202432603A (zh)	2022-12-20	2024-08-16	荷蘭商美勒斯公司	FAP結合域及結合FAP及TGF-βRII之雙特異性結合部分
WO2024136658A1 (en)	2022-12-23	2024-06-27	Merus N.V.	Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024143442A1 (ja) *	2022-12-27	2024-07-04	中外製薬株式会社	会合が制御されたポリペプチド
WO2024144401A1 (en)	2022-12-28	2024-07-04	Merus N.V.	Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2024153722A1 (en)	2023-01-20	2024-07-25	F. Hoffmann-La Roche Ag	Immunoconjugates
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
WO2024163009A1 (en)	2023-01-31	2024-08-08	Genentech, Inc.	Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh)	2023-01-31	2024-09-16	瑞士商赫孚孟拉羅股份公司	治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024184287A1 (en)	2023-03-06	2024-09-12	F. Hoffmann-La Roche Ag	Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188965A1 (en)	2023-03-13	2024-09-19	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
EP4438624A1 (en)	2023-03-27	2024-10-02	LAVA Therapeutics N.V.	Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024200573A1 (en)	2023-03-27	2024-10-03	LAVA Therapeutics N.V.	Nectin-4 binding agents and methods of use
WO2024208776A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	Agonistic split antibodies
WO2024208777A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	All-in-one agonistic antibodies
WO2024208898A1 (en)	2023-04-05	2024-10-10	Genmab A/S	Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
WO2024231320A1 (en)	2023-05-08	2024-11-14	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
US20240376221A1 (en)	2023-05-12	2024-11-14	Genmab A/S	Antibodies capable of binding to ox40, variants thereof and uses thereof
WO2024238537A1 (en)	2023-05-16	2024-11-21	F. Hoffmann-La Roche Ag	Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2025007037A1 (en)	2023-06-28	2025-01-02	Dragonfly Therapeutics, Inc.	Variant il-2 proteins
WO2025003280A1 (en)	2023-06-30	2025-01-02	Genmab A/S	Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025012118A2 (en)	2023-07-07	2025-01-16	LAVA Therapeutics N.V.	5t4 binding agents and methods of use
WO2025021838A1 (en)	2023-07-26	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025024780A1 (en)	2023-07-27	2025-01-30	LAVA Therapeutics N.V.	Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025027511A1 (en)	2023-07-30	2025-02-06	Janssen Biotech, Inc.	Molecules that bind to mutant calreticulin and uses thereof
WO2025034715A1 (en)	2023-08-07	2025-02-13	Janssen Biotech, Inc.	Gucy2c antibodies and uses thereof
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025036892A1 (en)	2023-08-14	2025-02-20	Morphosys Ag	Cycat halfbody molecules comprising sterically occluding moieties
WO2025042742A1 (en)	2023-08-18	2025-02-27	Bristol-Myers Squibb Company	Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
AU600885B2 (en)	1984-05-25	1990-08-30	Zymogenetics Inc.	Stable DNA constructs
DE3583667D1 (de)	1984-12-28	1991-09-05	Atochem	Druckfarbe mit einem strahlenhaertbaren makromer.
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en)	1986-02-19	1989-09-19	Enzo Biochem, Inc.	Analyte detection by means of energy transfer
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
US4801687A (en)	1986-10-27	1989-01-31	Bioprobe International, Inc.	Monoclonal antibody purification process using protein A
EP0307667B1 (en)	1987-08-24	1994-04-20	Wacom Company, Ltd.	Coordinate input system with input pen
US4937190A (en)	1987-10-15	1990-06-26	Wisconsin Alumni Research Foundation	Translation enhancer
NZ226694A (en)	1987-10-28	1994-04-27	Oncogen	Human immunoglobulin produced by recombinant dna techniques
ATE81724T1 (de)	1987-11-09	1992-11-15	Becton Dickinson Co	Verfahren zur analyse haematopoietischer zellen in einer probe.
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
AU4308689A (en)	1988-09-02	1990-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8909218D0 (en)	1989-04-22	1989-06-07	Medical Res Council	Improvements in or relating to enhancers
ES2062364T3 (es)	1989-06-08	1994-12-16	Wistar Inst	Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
WO1991000906A1 (en)	1989-07-12	1991-01-24	Genetics Institute, Inc.	Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en)	1989-08-11	1991-07-09	Becton, Dickinson And Company	Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5151504A (en)	1989-11-17	1992-09-29	E. R. Squibb & Sons, Inc.	Method for purification of monoclonal antibodies
RU2095414C1 (ru)	1989-12-01	1997-11-10	Джен Фарминг Ойроп БВ	Трансген для получения рекомбинантного полипептида в молоке трансгенных коров, способ получения трансгенной коровы (варианты), молоко от трансгенной коровы, пищевой состав
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
DE4006630A1 (de)	1990-03-03	1991-09-12	Behringwerke Ag	Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
EP0585287B1 (en)	1990-07-10	1999-10-13	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0469897A3 (en)	1990-07-31	1992-11-19	The Wistar Institute	Engineered antibodies
IE76732B1 (en)	1990-08-07	1997-11-05	Becton Dickinson Co	One step test for absolute counts
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en)	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgenic mice capable of producing heterologous antibodies
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
ATE164395T1 (de)	1990-12-03	1998-04-15	Genentech Inc	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK1279731T3 (da)	1991-03-01	2007-09-24	Dyax Corp	Fremgangsmåde til udvikling af bindende miniproteiner
JP3438889B2 (ja)	1991-03-29	2003-08-18	ジェネンテク，インコーポレイテッド	所望のタンパク質を高レベルに発現させる組換え宿主細胞の選別法
DE69233367T2 (de)	1991-04-10	2005-05-25	The Scripps Research Institute, La Jolla	Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
EP0523949B1 (en)	1991-07-15	2003-06-25	The Wellcome Foundation Limited	Production of antibodies
CA2087413A1 (en)	1992-01-17	1993-07-18	Joseph R. Lakowicz	Fluorescent energy transfer immunoassay
US7067284B1 (en)	1992-01-27	2006-06-27	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en)	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv)	1992-06-29	1992-06-29	Pharmacia Biosensor Ab	Improvement in optical assays
CA2137558A1 (en)	1992-07-17	1994-02-03	Wayne A. Marasco	Method of intracellular binding of target molecules
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
ES2309119T3 (es)	1992-10-28	2008-12-16	Genentech, Inc.	Utilizacion de antagonistas del factor de crecimiento celular vegf.
EP0669986B1 (en)	1992-11-13	2003-04-09	Idec Pharmaceuticals Corporation	Fully impaired consensus kozac sequences for mammalian expression
WO1994023046A1 (en)	1993-04-07	1994-10-13	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
DE69427974T2 (de)	1993-04-29	2001-12-06	Unilever N.V., Rotterdam	Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5693506A (en)	1993-11-16	1997-12-02	The Regents Of The University Of California	Process for protein production in plants
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
DE69430014D1 (de)	1993-12-23	2002-04-04	Infigen Inc	EMBRYONALE STAMMZELLEN von Huftieren ALS KERNDONATOREN UND KERNTRANSFERTECHNIKEN ZUR HERSTELLUNG CHIMÄRER UND TRANSGENER TIERE
DK1231268T3 (da)	1994-01-31	2005-11-21	Univ Boston	Polyklonale antistofbiblioteker
FR2717187B1 (fr)	1994-03-10	1996-05-31	Transgene Sa	Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en)	1994-07-25	2000-06-27	Monsanto Company	Method for producing antibodies in plant cells
JPH08116978A (ja)	1994-10-18	1996-05-14	Nisshinbo Ind Inc	抗体Ｆａｂライブラリーの作製法
ES2292173T3 (es)	1994-12-30	2008-03-01	Planet Biotechnology, Inc.	Procedimiento para producir inmunoglobulinas que contienen proteinas de proteccion en plantas y sus usos.
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
US5783186A (en)	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis
US5885827A (en)	1996-01-23	1999-03-23	The Regents Of The Universtiy Of California	Eukaryotic high rate mutagenesis system
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6825396B2 (en)	1996-06-12	2004-11-30	Board Of Trustees Operating Michigan State University	Methods for tissue specific synthesis of protein in eggs of transgenic hens
DE69718341T2 (de)	1996-10-08	2003-10-30	U-Bisys B.V., Utrecht	Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
GB9621113D0 (en)	1996-10-10	1996-11-27	Univ Southampton	Transgenic fish
CA2273192A1 (en)	1996-12-02	1998-06-11	Wake Forest University	Inactivation of hiv co-receptors as therapy for hiv infection
WO1998031700A1 (en)	1997-01-21	1998-07-23	The General Hospital Corporation	Selection of proteins using rna-protein fusions
JP2002512510A (ja)	1997-03-06	2002-04-23	インフィジェン・インコーポレーテッド	動物のクローニング方法
BR9808584A (pt)	1997-03-14	2000-05-23	Idec Pharma Corp	Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6080912A (en)	1997-03-20	2000-06-27	Wisconsin Alumni Research Foundation	Methods for creating transgenic animals
CN100480269C (zh)	1997-04-07	2009-04-22	基因技术股份有限公司	抗-血管内皮生长因子的抗体
WO1999026569A1 (fr)	1997-11-26	1999-06-03	Mitsubishi Precision Co., Ltd.	Systeme de guidages a informations
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en)	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
CA2288600C (en)	1997-05-02	2010-06-01	Genentech, Inc.	A method for making multispecific antibodies having heteromultimeric and common components
AU736549B2 (en)	1997-05-21	2001-08-02	Merck Patent Gesellschaft Mit Beschrankter Haftung	Method for the production of non-immunogenic proteins
IL134897A0 (en)	1997-09-23	2001-05-20	Oxford Biomedica Ltd	Expression of genes in hematopoietic stem cells in ischemic conditions
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
CN1203178C (zh)	1997-10-27	2005-05-25	尤尼利弗公司	多价抗原结合蛋白
NZ506895A (en)	1998-03-30	2003-09-26	Res Dev Foundation	Corticotropin releasing factor receptor 1-deficient mice
US6413776B1 (en)	1998-06-12	2002-07-02	Galapagos Geonomics N.V.	High throughput screening of gene function using adenoviral libraries for functional genomics applications
GB9823930D0 (en)	1998-11-03	1998-12-30	Babraham Inst	Murine expression of human ig\ locus
JP2002536968A (ja)	1999-01-29	2002-11-05	イムクローンシステムズインコーポレイティド	Ｋｄｒに特異的な抗体およびその使用
PT1161548E (pt)	1999-04-15	2005-06-30	Crucell Holland Bv	Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
PT2067788E (pt)	1999-05-18	2015-10-29	Dyax Corp	Bibliotecas de fragmentos fab e métodos para a sua utilização
US6472147B1 (en)	1999-05-25	2002-10-29	The Scripps Research Institute	Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
BR122014028365B8 (pt)	1999-06-25	2021-07-06	Genentech Inc	artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
WO2001019394A2 (en)	1999-09-15	2001-03-22	Therapeutic Human Polyclonals, Inc.	Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
US6180357B1 (en)	1999-10-08	2001-01-30	Arius Research, Inc.	Individualized patient-specific anti-cancer antibodies
AU7676300A (en)	1999-10-12	2001-04-23	Cambridge Antibody Technology Limited	Human anti-adipocyte monoclonal antibodies and their use
CA2389633A1 (en)	1999-11-01	2001-05-10	Chiron Corporation	Expression vectors, transfection systems, and method of use thereof
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
EP1273918B1 (en)	1999-12-27	2008-02-20	Crucell Holland B.V.	Antibodies against Ep-Cam
EP1268832A4 (en)	2000-02-29	2003-04-02	Univ Auburn	PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTIDES
US20040180046A1 (en)	2000-04-26	2004-09-16	Jeff Himawan	Bispecific molecules and uses thereof
AU2001265953B2 (en)	2000-05-12	2005-09-29	D. Collen Research Foundation Vzw	Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
IL152825A (en)	2000-05-16	2009-07-20	Univ Jefferson	Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
UY26807A1 (es)	2000-06-29	2002-01-31	Abbott Lab	Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
EP1184458A1 (en)	2000-08-28	2002-03-06	U-BISys B.V.	Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en)	2000-09-15	2002-03-20	U-BISys B.V.	Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en)	2000-10-18	2010-06-15	Sloan-Kettering Institute For Cancer Research	Uses of monoclonal antibody 8H9
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
PT1354034E (pt)	2000-11-30	2008-02-28	Medarex Inc	Roedores transgénicos transcromossómicos para produção de anticorpos humanos
FR2817875B1 (fr)	2000-12-07	2005-03-18	Technopharm	Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
AU2002227883A1 (en)	2001-01-25	2002-08-06	Evolva Biotech A/S	A library of a collection of cells
JP4307079B2 (ja)	2001-01-26	2009-08-05	セレキスエスアー	マトリックス付着領域およびその使用方法
US7319139B2 (en)	2001-01-29	2008-01-15	Biogen Idec, Inc.	TAG-72 specific CH2 domain deleted antibodies
EP2294917A1 (en)	2001-03-22	2011-03-16	Abbott GmbH & Co. KG	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
GB0110029D0 (en)	2001-04-24	2001-06-13	Grosveld Frank	Transgenic animal
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR20090125840A (ko)	2001-06-13	2009-12-07	젠맵 에이/에스	표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
AU2002345421B2 (en)	2001-06-15	2006-11-16	Crucell Holland B.V.	Chimaeric phages
WO2004003211A1 (en)	2002-06-26	2004-01-08	Imclone Systems Incorporated	Bispecific antibodies that bind to vegf receptors
JP4303105B2 (ja)	2001-06-28	2009-07-29	ドマンティスリミテッド	二重特異性リガンドとその利用
JP4500044B2 (ja)	2001-07-04	2010-07-14	クロマジェニックスビー．ブイ．	遺伝子転写を調節する特性を含むｄｎａ配列及びそのようなｄｎａ配列を検出し且つ使用するための方法
WO2003016501A2 (en)	2001-08-21	2003-02-27	Thomas Jefferson University	Recombinant antibodies, and compositions and methods for making and using the same
MXPA04001566A (es)	2001-08-27	2004-05-17	Genentech Inc	Un sistema para expresion y ensamblado de anticuerpos.
AU2002364956C1 (en)	2001-11-16	2009-05-28	Biogen Idec Inc.	Polycistronic expression of antibodies
AU2002363861A1 (en)	2001-11-30	2003-06-10	Crucell Holland B.V.	Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
DE60226486D1 (de)	2001-11-30	2008-06-19	Ca Nat Research Council	Selbstanordnende moleküle
GB0130267D0 (en)	2001-12-19	2002-02-06	Neutec Pharma Plc	Focussed antibody technology
US7244592B2 (en)	2002-03-07	2007-07-17	Dyax Corp.	Ligand screening and discovery
GB2387030A (en)	2002-03-26	2003-10-01	Thales Plc	Compensation of mutual coupling in array antenna systems
US20050130224A1 (en)	2002-05-31	2005-06-16	Celestar Lexico- Sciences, Inc.	Interaction predicting device
NZ556507A (en)	2002-06-03	2010-03-26	Genentech Inc	Synthetic antibody phage libraries
CA2722998C (en)	2002-06-14	2014-12-02	Chromagenics B.V.	A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en)	2002-06-14	2003-12-24	Chromagenics B.V.	Means and methods for regulating gene expression
US20080241166A1 (en)	2002-06-28	2008-10-02	Domantis Limited	Ligands that bind a receptor
CN1328446C (zh)	2002-07-10	2007-07-25	阿戈什蒂诺·迪特拉帕尼	建筑元件
JP4836451B2 (ja)	2002-07-18	2011-12-14	メルスベーヴェー	抗体混合物の組換え生産
EA013225B1 (ru)	2003-01-07	2010-04-30	Симфоген А/С	Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
EP1439234A1 (en)	2003-01-08	2004-07-21	ARTEMIS Pharmaceuticals GmbH	Targeted transgenesis using the rosa26 locus
EP2395016A3 (en)	2003-05-30	2012-12-19	Merus B.V.	Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP1636265A2 (en)	2003-06-25	2006-03-22	Crucell Holland B.V.	Binding molecules for the treatment of myeloid cell malignancies
AU2004260884B2 (en)	2003-07-22	2009-11-19	Crucell Holland B.V.	Binding molecules against SARS-coronavirus and uses thereof
WO2005063819A2 (en)	2003-12-23	2005-07-14	Crucell Holland B.V.	Human binding molecule against cd1a
JP5912211B2 (ja)	2004-01-20	2016-04-27	メルスビー．ヴィー．	結合タンパク質の混合物
PL2314621T3 (pl)	2004-05-27	2014-08-29	Crucell Holland Bv	Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
AU2005250499B2 (en)	2004-06-03	2011-12-08	Novimmune S.A.	Anti-CD3 antibodies and methods of use thereof
JP2008511337A (ja)	2004-09-02	2008-04-17	ジェネンテック・インコーポレーテッド	ヘテロ多量体分子
JP4487068B2 (ja)	2004-10-12	2010-06-23	国立大学法人岡山大学	細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
AU2005293560B2 (en)	2004-10-12	2011-10-06	Crucell Holland B.V.	Binding molecules for treatment and detection of cancer
SG159542A1 (en)	2004-11-11	2010-03-30	Crucell Holland Bv	Compositions against sars-coronavirus and uses thereof
DK3050963T3 (da)	2005-03-31	2019-12-09	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
JP2008538912A (ja)	2005-04-29	2008-11-13	イナート・ファルマ	遺伝子導入動物および組換え抗体の製造方法
CA2608058C (en)	2005-05-12	2013-09-10	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (en)	2005-06-23	2008-03-05	Crucell Holland B.V.	Optimization of west nile virus antibodies
AU2006290736B2 (en)	2005-09-15	2011-09-15	Crucell Holland B.V.	Method for preparing immunoglobulin libraries
KR20080090406A (ko)	2005-11-28	2008-10-08	젠맵 에이/에스	재조합 １가 항체 및 그의 제조 방법
CN101370526B (zh) *	2005-11-28	2013-10-09	根马布股份公司	重组单价抗体及其制备方法
US8871912B2 (en)	2006-03-24	2014-10-28	Merck Patent Gmbh	Engineered heterodimeric protein domains
CA2638774C (en)	2006-03-31	2015-11-24	Medarex, Inc.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
RS52643B (en)	2006-06-02	2013-06-28	Regeneron Pharmaceuticals Inc.	High affinity antibodies to human il-6 receptor
CN101460519B (zh)	2006-06-06	2013-06-19	克鲁塞尔荷兰公司	具有杀灭葡萄球菌活性的人结合分子及其应用
EP2024394B1 (en)	2006-06-06	2014-11-05	Crucell Holland B.V.	Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
EP2035456A1 (en)	2006-06-22	2009-03-18	Novo Nordisk A/S	Production of bispecific antibodies
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
KR101485197B1 (ko)	2006-09-07	2015-01-23	크루셀 홀란드 비.브이.	인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
ES2466669T3 (es)	2006-10-02	2014-06-10	Regeneron Pharmaceuticals, Inc.	Anticuerpos humanos con alta afinidad para el receptor IL-4 humano
US8290739B2 (en)	2006-10-20	2012-10-16	Amfit, Inc.	Method for determining relative mobility of regions of an object
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN104497143B (zh)	2007-03-29	2020-08-25	健玛保	双特异性抗体及其制造方法
ITMI20071522A1 (it)	2007-07-27	2009-01-28	Areta Internat S R L	Vaccino idiotipico
CA2695374A1 (en)	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
BRPI0816785A2 (pt)	2007-09-14	2017-05-02	Adimab Inc	bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
WO2009051974A1 (en)	2007-10-17	2009-04-23	Nuvelo, Inc.	Antibodes to cll-1
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
SI2235064T1 (sl)	2008-01-07	2016-04-29	Amgen Inc.	Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2245571B1 (en)	2008-02-05	2019-04-10	Zymeworks Inc.	Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
KR101990228B1 (ko)	2008-06-27	2019-06-17	메뤼스 엔.페.	항체 생산 비-인간 포유동물
CN102365296A (zh) *	2009-01-26	2012-02-29	根马布股份公司	用于生成抗体混合物的方法
TW201438739A (zh)	2009-03-20	2014-10-16	Genentech Inc	抗-ｈｅｒ抗體
EP2424567B1 (en)	2009-04-27	2018-11-21	OncoMed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
WO2010130636A1 (en)	2009-05-11	2010-11-18	Crucell Holland B.V.	Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
PL2975051T3 (pl)	2009-06-26	2021-09-20	Regeneron Pharmaceuticals, Inc.	Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
US8765900B2 (en)	2009-08-27	2014-07-01	Bayer Materialscience Llc	Aliphatic moisture-curable resins, coating compositions, and related processes
US9493578B2 (en) *	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2504360B1 (en)	2009-11-23	2018-08-15	Amgen Inc.	Monomeric antibody fc
CN102791866B (zh)	2010-02-08	2015-07-29	瑞泽恩制药公司	共有轻链小鼠
US20120021409A1 (en)	2010-02-08	2012-01-26	Regeneron Pharmaceuticals, Inc.	Common Light Chain Mouse
CA2797981C (en) *	2010-05-14	2019-04-23	Rinat Neuroscience Corporation	Heterodimeric proteins and methods for producing and purifying them
WO2012020096A1 (en) *	2010-08-13	2012-02-16	Medimmune Limited	Monomeric polypeptides comprising variant fc regions and methods of use
DK2606064T3 (da)	2010-08-16	2015-04-20	Novimmune Sa	Fremgangsmåder til generering af multispecifikke og multivalente antistoffer
HUE047228T2 (hu) *	2010-11-05	2020-04-28	Zymeworks Inc	Stabil heterodimer antitest-kialakítás az FC doménben mutációval
PL2550363T3 (pl)	2011-02-25	2015-05-29	Regeneron Pharma	Myszy adam6
CN108285488B (zh)	2011-03-25	2023-01-24	伊克诺斯科学公司	异二聚体免疫球蛋白
JP2013004215A (ja)	2011-06-14	2013-01-07	Hitachi Ltd	リチウムイオン二次電池
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
CA2865029A1 (en)	2012-03-06	2013-09-12	Regeneron Pharmaceuticals, Inc.	Common light chain mouse
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
RU2014153674A (ru)	2012-06-05	2016-07-27	Регенерон Фармасьютикалз, Инк.	Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
BR112015006824A2 (pt)	2012-09-27	2017-07-04	Merus B V	anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
UY35148A (es) *	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US10798961B2 (en)	2013-03-15	2020-10-13	Altria Client Services Llc	Functional food and beverage compositions with improved taste through the use of sensates
RS57928B1 (sr)	2015-07-10	2019-01-31	Merus Nv	Antitela koja vezuju humani cd3

2013
- 2013-04-19 DK DK13720615.7T patent/DK2838918T3/da active
- 2013-04-19 US US13/866,756 patent/US9248182B2/en active Active
- 2013-04-19 KR KR1020147032231A patent/KR102104601B1/ko active Active
- 2013-04-19 SM SM20190488T patent/SMT201900488T1/it unknown
- 2013-04-19 DK DK13720614.0T patent/DK2838917T3/da active
- 2013-04-19 KR KR1020237019942A patent/KR20230091201A/ko active Pending
- 2013-04-19 SG SG11201406770WA patent/SG11201406770WA/en unknown
- 2013-04-19 MX MX2014012700A patent/MX360109B/es active IP Right Grant
- 2013-04-19 US US14/395,330 patent/US20150139996A1/en not_active Abandoned
- 2013-04-19 SG SG10201607369QA patent/SG10201607369QA/en unknown
- 2013-04-19 EP EP13720614.0A patent/EP2838917B1/en active Active
- 2013-04-19 KR KR1020207030488A patent/KR20200126007A/ko not_active Ceased
- 2013-04-19 CN CN201380032276.1A patent/CN104520320B/zh active Active
- 2013-04-19 WO PCT/NL2013/050294 patent/WO2013157954A1/en active Application Filing
- 2013-04-19 NZ NZ630551A patent/NZ630551A/en unknown
- 2013-04-19 NZ NZ772318A patent/NZ772318A/en unknown
- 2013-04-19 AU AU2013249986A patent/AU2013249986B2/en active Active
- 2013-04-19 SG SG11201406772YA patent/SG11201406772YA/en unknown
- 2013-04-19 KR KR1020227011508A patent/KR102545770B1/ko active Active
- 2013-04-19 EA EA201491908A patent/EA201491908A1/ru unknown
- 2013-04-19 PL PL13720614T patent/PL2838917T3/pl unknown
- 2013-04-19 PT PT13720614T patent/PT2838917T/pt unknown
- 2013-04-19 AU AU2013249985A patent/AU2013249985B2/en active Active
- 2013-04-19 LT LTEP13720614.0T patent/LT2838917T/lt unknown
- 2013-04-19 SI SI201331553T patent/SI2838917T1/sl unknown
- 2013-04-19 JP JP2015506927A patent/JP6272299B2/ja active Active
- 2013-04-19 CA CA2871068A patent/CA2871068C/en active Active
- 2013-04-19 SG SG10201913634VA patent/SG10201913634VA/en unknown
- 2013-04-19 PL PL13720615T patent/PL2838918T3/pl unknown
- 2013-04-19 KR KR1020257003984A patent/KR20250025034A/ko active Pending
- 2013-04-19 KR KR1020237019940A patent/KR20230093359A/ko active Pending
- 2013-04-19 CN CN201380032190.9A patent/CN104520319B/zh active Active
- 2013-04-19 LT LTEP13720615.7T patent/LT2838918T/lt unknown
- 2013-04-19 EA EA202090591A patent/EA202090591A3/ru unknown
- 2013-04-19 PT PT13720615T patent/PT2838918T/pt unknown
- 2013-04-19 ES ES13720614T patent/ES2743399T3/es active Active
- 2013-04-19 CA CA2870821A patent/CA2870821C/en active Active
- 2013-04-19 NZ NZ630568A patent/NZ630568A/en unknown
- 2013-04-19 EA EA201491909A patent/EA035344B1/ru not_active IP Right Cessation
- 2013-04-19 HU HUE13720615A patent/HUE045945T2/hu unknown
- 2013-04-19 RS RSP20191034 patent/RS59263B1/sr unknown
- 2013-04-19 EP EP19178196.2A patent/EP3594233A1/en active Pending
- 2013-04-19 KR KR1020207011173A patent/KR102382304B1/ko active Active
- 2013-04-19 ES ES13720615T patent/ES2740749T3/es active Active
- 2013-04-19 WO PCT/NL2013/050293 patent/WO2013157953A1/en active Application Filing
- 2013-04-19 JP JP2015506928A patent/JP6393255B2/ja active Active
- 2013-04-19 SG SG10201913376XA patent/SG10201913376XA/en unknown
- 2013-04-19 NZ NZ799532A patent/NZ799532A/en unknown
- 2013-04-19 CN CN202111365429.7A patent/CN114163530A/zh active Pending
- 2013-04-19 EP EP19177410.8A patent/EP3594232A1/en active Pending
- 2013-04-19 US US13/866,747 patent/US9248181B2/en active Active
- 2013-04-19 US US14/395,325 patent/US20150196637A1/en not_active Abandoned
- 2013-04-19 SM SM20190493T patent/SMT201900493T1/it unknown
- 2013-04-19 KR KR1020207001067A patent/KR102269650B1/ko active Active
- 2013-04-19 CN CN201710637343.2A patent/CN107383197B/zh active Active
- 2013-04-19 KR KR1020147032229A patent/KR102171431B1/ko active Active
- 2013-04-19 CN CN201810296908.XA patent/CN108586610A/zh active Pending
- 2013-04-19 EP EP13720615.7A patent/EP2838918B1/en active Active
- 2013-04-19 RS RSP20190999 patent/RS59260B1/sr unknown
- 2013-04-19 SG SG10201607371UA patent/SG10201607371UA/en unknown
- 2013-04-19 SI SI201331534T patent/SI2838918T1/sl unknown
- 2013-04-19 MX MX2014012701A patent/MX360110B/es active IP Right Grant
- 2013-04-19 HU HUE13720614A patent/HUE045944T2/hu unknown
- 2013-11-15 US US14/081,848 patent/US9358286B2/en active Active
2014
- 2014-10-20 MX MX2018012769A patent/MX2018012769A/es unknown
- 2014-10-20 MX MX2018012766A patent/MX2018012766A/es unknown
- 2014-10-27 ZA ZA2014/07835A patent/ZA201407835B/en unknown
- 2014-10-27 ZA ZA2014/07834A patent/ZA201407834B/en unknown
2015
- 2015-07-10 HK HK15106583.3A patent/HK1206039A1/xx unknown
- 2015-07-15 HK HK15106743.0A patent/HK1206041A1/xx unknown
- 2015-12-18 US US14/974,581 patent/US9758805B2/en active Active
2016
- 2016-05-16 US US15/155,743 patent/US10329596B2/en active Active
2017
- 2017-04-25 US US15/496,807 patent/US10337045B2/en active Active
- 2017-12-28 JP JP2017254422A patent/JP6639464B2/ja active Active
2018
- 2018-02-23 AU AU2018201326A patent/AU2018201326B2/en active Active
- 2018-02-23 AU AU2018201325A patent/AU2018201325B2/en active Active
- 2018-08-24 JP JP2018157537A patent/JP6781740B2/ja active Active
2019
- 2019-05-20 US US16/417,379 patent/US10752929B2/en active Active
- 2019-08-02 HR HRP20191409 patent/HRP20191409T1/hr unknown
- 2019-08-05 CY CY20191100831T patent/CY1122153T1/el unknown
- 2019-08-09 HR HRP20191446 patent/HRP20191446T1/hr unknown
- 2019-08-28 CY CY20191100914T patent/CY1122118T1/el unknown
- 2019-12-24 JP JP2019233206A patent/JP2020089366A/ja active Pending
2020
- 2020-07-21 US US16/934,925 patent/US12123043B2/en active Active
- 2020-08-20 JP JP2020139295A patent/JP2020202854A/ja active Pending
2023
- 2023-02-28 JP JP2023030194A patent/JP2023060019A/ja active Pending
- 2023-05-16 US US18/318,507 patent/US11926859B2/en active Active
2024
- 2024-02-02 US US18/431,564 patent/US20240344102A1/en active Pending
- 2024-10-07 JP JP2024175774A patent/JP2024180421A/ja active Pending

Also Published As

Publication number	Publication date
CN104520319B (zh)	2017-08-25
ES2743399T3 (es)	2020-02-19
PT2838918T (pt)	2019-08-23
US12123043B2 (en)	2024-10-22
US10337045B2 (en)	2019-07-02
AU2018201325B2 (en)	2020-02-06
NZ728228A (en)	2021-02-26
EP2838917B1 (en)	2019-06-05
CA2871068A1 (en)	2013-10-24
US20230340556A1 (en)	2023-10-26
SG10201913376XA (en)	2020-02-27
AU2018201325A1 (en)	2018-03-15
SI2838918T1 (sl)	2019-11-29
HK1206041A1 (zh)	2015-12-31
SG10201607369QA (en)	2016-10-28
KR102382304B1 (ko)	2022-04-04
EA202090591A3 (ru)	2020-12-30
WO2013157953A1 (en)	2013-10-24
US20140140999A1 (en)	2014-05-22
EP2838918A1 (en)	2015-02-25
ES2740749T3 (es)	2020-02-06
JP6393255B2 (ja)	2018-09-19
MX2014012700A (es)	2014-12-05
SG11201406770WA (en)	2014-11-27
ZA201407834B (en)	2015-12-23
EA201491908A1 (ru)	2015-03-31
EP2838918B1 (en)	2019-06-05
US20170369923A1 (en)	2017-12-28
JP2015514417A (ja)	2015-05-21
HRP20191409T1 (hr)	2019-11-15
EP2838917A1 (en)	2015-02-25
AU2013249985A1 (en)	2014-11-06
SG10201607371UA (en)	2016-10-28
MX2018012766A (es)	2021-11-16
AU2018201326B2 (en)	2020-02-06
KR20150035535A (ko)	2015-04-06
HUE045944T2 (hu)	2020-02-28
KR20150035534A (ko)	2015-04-06
JP2020202854A (ja)	2020-12-24
CA2870821A1 (en)	2013-10-24
CN107383197B (zh)	2021-12-10
MX2018012769A (es)	2021-11-16
KR102545770B1 (ko)	2023-06-21
RS59260B1 (sr)	2019-10-31
WO2013157954A1 (en)	2013-10-24
CY1122153T1 (el)	2020-11-25
SMT201900493T1 (it)	2019-11-13
CY1122118T1 (el)	2020-11-25
MX360110B (es)	2018-10-23
ZA201407835B (en)	2015-12-23
EP3594233A1 (en)	2020-01-15
US9248181B2 (en)	2016-02-02
AU2013249986B2 (en)	2017-11-23
CN107383197A (zh)	2017-11-24
KR20230093359A (ko)	2023-06-27
MX360109B (es)	2018-10-23
CN104520320B (zh)	2018-05-01
CA2870821C (en)	2022-06-14
JP2023060019A (ja)	2023-04-27
NZ630568A (en)	2017-06-30
US20210071222A1 (en)	2021-03-11
US20150196637A1 (en)	2015-07-16
JP6639464B2 (ja)	2020-02-05
DK2838917T3 (da)	2019-08-26
KR20200015756A (ko)	2020-02-12
MX2014012701A (es)	2014-12-05
US9758805B2 (en)	2017-09-12
HRP20191446T1 (hr)	2019-11-15
KR20250025034A (ko)	2025-02-20
CN104520320A (zh)	2015-04-15
SG11201406772YA (en)	2014-11-27
CN114163530A (zh)	2022-03-11
US20160177364A1 (en)	2016-06-23
KR102269650B1 (ko)	2021-06-28
AU2018201326A1 (en)	2018-03-15
LT2838917T (lt)	2019-09-25
US20240344102A1 (en)	2024-10-17
US20200017897A1 (en)	2020-01-16
NZ630551A (en)	2017-11-24
EA201491909A1 (ru)	2015-03-31
AU2013249986A1 (en)	2014-11-06
KR20200047724A (ko)	2020-05-07
RS59263B1 (sr)	2019-10-31
CA2871068C (en)	2022-06-14
JP2015515275A (ja)	2015-05-28
US20170327860A1 (en)	2017-11-16
NZ772318A (en)	2023-06-30
JP2024180421A (ja)	2024-12-26
AU2013249985B2 (en)	2017-11-23
JP6272299B2 (ja)	2018-01-31
JP2020089366A (ja)	2020-06-11
US20130336981A1 (en)	2013-12-19
PL2838918T3 (pl)	2019-11-29
NZ799532A (en)	2023-07-28
EA035344B1 (ru)	2020-05-29
SMT201900488T1 (it)	2019-11-13
US20140072579A1 (en)	2014-03-13
KR20220046711A (ko)	2022-04-14
JP2018099119A (ja)	2018-06-28
KR102104601B1 (ko)	2020-06-01
US10752929B2 (en)	2020-08-25
SG10201913634VA (en)	2020-03-30
US9248182B2 (en)	2016-02-02
JP2019022489A (ja)	2019-02-14
EA202090591A2 (ru)	2020-08-31
KR102171431B1 (ko)	2020-10-30
CN108586610A (zh)	2018-09-28
US11926859B2 (en)	2024-03-12
EP3594232A1 (en)	2020-01-15
US10329596B2 (en)	2019-06-25
PT2838917T (pt)	2019-09-12
SI2838917T1 (sl)	2019-11-29
US20150139996A1 (en)	2015-05-21
PL2838917T3 (pl)	2019-12-31
LT2838918T (lt)	2019-09-10
HK1206039A1 (zh)	2015-12-31
HUE045945T2 (hu)	2020-02-28
JP6781740B2 (ja)	2020-11-04
CN104520319A (zh)	2015-04-15
KR20200126007A (ko)	2020-11-05
US9358286B2 (en)	2016-06-07
KR20230091201A (ko)	2023-06-22

Publication	Publication Date	Title
DK2838918T3 (da)	2019-08-12	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
DK2972353T3 (da)	2023-03-27	Forbedrede fremgangsmåder til udførelse af multipleksanalyser
DK2800565T3 (da)	2020-04-27	Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK3363901T3 (da)	2021-02-22	Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2906696T3 (da)	2019-11-25	Fremgangsmåder til modulering af c9orf72-ekspression
DK3421051T3 (da)	2020-06-22	Fremgangsmåder til glycokonjugering og sammensætninger
DK2867600T3 (da)	2019-06-03	System og fremgangsmåde til carbondioxidopfangning og -deponering
DK2925782T3 (da)	2020-04-06	Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2715520T3 (da)	2019-10-14	Systemer og metoder til udførelse af enhedsstyring
DK3312156T3 (da)	2019-07-22	Fremgangsmåder til fremstilling af (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethylamin
DK4011364T3 (da)	2024-03-18	Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
DK2708147T3 (da)	2020-05-18	Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
DK4011325T3 (da)	2025-02-03	Indretning til forankring af transplantat
DK2681084T3 (da)	2020-04-27	Indretning, system og fremgangsmåde til deling af køretøjer
DK3363805T3 (da)	2021-03-08	Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner
DK2908661T3 (da)	2020-02-03	Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK2922955T3 (da)	2019-05-13	Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK2858563T3 (da)	2021-10-04	Elektromedicinsk system til bestemmelse af neuromuskulkær lammelse
DK3296279T3 (da)	2022-09-05	Opløsningsmiddelsystemer af n-alkylthiophosphortriamider og fremgangsmåder til anvendelse inden for landbruget
DK2896694T3 (da)	2019-11-25	Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2977380T3 (da)	2019-01-02	Alkyleringsfremgangsmåde under anvendelse af phosphonium-baserede ioniske væsker
DK2916661T3 (da)	2019-06-03	Fremgangsmåde til opnåelse af bloom-hæmmende komponenter til konfektureprodukter
DK2872536T3 (da)	2019-11-25	Fremgangsmåde til ekstraktion af biomasse
DK2536399T3 (da)	2020-02-10	Fremgangsmåde til aktivering og konjugering af biomolekyler
DK2871184T3 (da)	2017-11-13	Benzodioxolderivat og fremgangsmåde til fremstilling og anvendelse deraf